Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

18
New Strong Sell Stocks for June 18th

2018-06-18 zacks
Waddell & Reed Financial, Inc. (WDR - Free Report) is a provider of investment management and advisory services. The Zacks Consensus Estimate for its current year earnings has been revised 1.4% downward over the last 30 days.
VIVHY WDR ENSG JBLU SITO VIV

2
Jay-Z defeats copyright claims over 'Big Pimpin''

2018-05-31 reuters
(Reuters) - A federal appeals court on Thursday awarded a victory to Jay-Z in a copyright infringement lawsuit claiming that the rapper sampled without permission from an Egyptian composer’s song for his 1999 hit “Big Pimpin’.”
VIA VIAB VIV

1
Italian stocks stage recovery bid as political drama rumbles on - MarketWatch

2018-05-30 marketwatch
Italian stocks moved higher Wednesday, recovering somewhat from a selloff driven by political instability in the country, as the broader European equity market steadied.
MON VIV

4
French Soccer Rights Soar as Chinese-Led Venture Outbids Canal+ - Bloomberg

2018-05-29 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BT.A BTGOF ILD VIV BT

1
Vivendi SA 2018 Q1 - Results - Earnings Call Slides

2018-05-18 seekingalpha
The following slide deck was published by Vivendi SA in conjunction with their 2018 Q1 earnings call.
VIVEF VIVHY VIV

0
Telecom Italia sales up on mobile growth

2018-05-18 thestar.com.my
MILAN: Telecom Italia SpA posted first-quarter sales that beat analysts’ estimates, driven by growth in domestic mobile and broadband subscriber numbers.
CKHUF ILD CKHUY VIV 8038

0
French Billionaire Is Too Much of a Mystery Man - Bloomberg

2018-05-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
MS VIV

0
Elliott Wins Clash for Telecom Italia’s Board, Beats Vivendi - Bloomberg

2018-05-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
VIV

0
Flash - Vivendi and activist fund set for Telecom Italia showdown - France 24

2018-05-04 france24
A weeks-long power struggle over the control of Telecom Italia between Vivendi and a US activist fund comes to a head Friday when shareholders vote on a new board.
VIV

0
Shareholders set for showdown over Telecom Italia

2018-05-04 thelocal.it
Vivendi, which is the largest shareholder in Telecom Italia (TIM) with a stake of around 24 percent, has been at loggerheads with activist fund Elliott – which holds just over nine percent – since Elliott demanded the removal of six board members in mid-March.
VIV

3
French billionaire facing charges after bribery probe

2018-04-25 theage.com.au
Billionaire Vincent Bollore was charged by French investigators as part of a probe into the possible use of bribes in two African countries to obtain port contracts from public officials, according to a statement from his company.
BOLRF SCGLF BOL SCGLY GLE VIV

3
French billionaire facing charges after bribery probe

2018-04-25 smh.com.au
Billionaire Vincent Bollore was charged by French investigators as part of a probe into the possible use of bribes in two African countries to obtain port contracts from public officials, according to a statement from his company.
BOLRF SCGLF BOL SCGLY GLE VIV

3
French billionaire charged after bribery probe

2018-04-25 theage.com.au
Billionaire Vincent Bollore was charged by French investigators as part of a probe into the possible use of bribes in two African countries to obtain port contracts from public officials, according to a statement from his company.
BOLRF SCGLF BOL SCGLY GLE VIV

3
French billionaire charged after bribery probe

2018-04-25 smh.com.au
Billionaire Vincent Bollore was charged by French investigators as part of a probe into the possible use of bribes in two African countries to obtain port contracts from public officials, according to a statement from his company.
BOLRF SCGLF BOL SCGLY GLE VIV

3
Billionaire Bollore Charged in French Bribery Investigation - Bloomberg

2018-04-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BOLRF SCGLF BOL SCGLY GLE VIV

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:VIV / VIVENDI on message board site Silicon Investor.

Survivalists, Disaster Preparedness and Living Off the Grid Revival
OTTV VIVALIVETV SI members discuss Survivor
Support the French! Viva Democracy! VIVO: MERIDIAN BIOSCIENCE INC(NASDAQ)
American Automobile Industry: Can it survive? VVUS: VIVUS INC. (NASDAQ)
NVIV NVIV - InVivo Therapeutics